JP2009502780A5 - - Google Patents

Download PDF

Info

Publication number
JP2009502780A5
JP2009502780A5 JP2008522796A JP2008522796A JP2009502780A5 JP 2009502780 A5 JP2009502780 A5 JP 2009502780A5 JP 2008522796 A JP2008522796 A JP 2008522796A JP 2008522796 A JP2008522796 A JP 2008522796A JP 2009502780 A5 JP2009502780 A5 JP 2009502780A5
Authority
JP
Japan
Prior art keywords
quinolin
pyrrolo
amido
pyridin
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008522796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009502780A (ja
JP5242391B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/025377 external-priority patent/WO2007018818A1/en
Publication of JP2009502780A publication Critical patent/JP2009502780A/ja
Publication of JP2009502780A5 publication Critical patent/JP2009502780A5/ja
Application granted granted Critical
Publication of JP5242391B2 publication Critical patent/JP5242391B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008522796A 2005-07-22 2006-06-29 Tgf−ベータ阻害剤としてのピリジンキノリン置換ピロロ[1,2−b]ピラゾール一水和物 Expired - Fee Related JP5242391B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70164105P 2005-07-22 2005-07-22
US60/701,641 2005-07-22
PCT/US2006/025377 WO2007018818A1 (en) 2005-07-22 2006-06-29 A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor

Publications (3)

Publication Number Publication Date
JP2009502780A JP2009502780A (ja) 2009-01-29
JP2009502780A5 true JP2009502780A5 (https=) 2009-08-20
JP5242391B2 JP5242391B2 (ja) 2013-07-24

Family

ID=37450942

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008522796A Expired - Fee Related JP5242391B2 (ja) 2005-07-22 2006-06-29 Tgf−ベータ阻害剤としてのピリジンキノリン置換ピロロ[1,2−b]ピラゾール一水和物

Country Status (16)

Country Link
US (1) US7872020B2 (https=)
EP (1) EP1910370B1 (https=)
JP (1) JP5242391B2 (https=)
BR (1) BRPI0613639A2 (https=)
CA (1) CA2616196C (https=)
DK (1) DK1910370T3 (https=)
ES (1) ES2542425T3 (https=)
HR (1) HRP20150474T1 (https=)
HU (1) HUE025209T2 (https=)
IL (1) IL188181A (https=)
MX (1) MX2008001020A (https=)
PL (1) PL1910370T3 (https=)
PT (1) PT1910370E (https=)
RS (1) RS53999B1 (https=)
SI (1) SI1910370T1 (https=)
WO (1) WO2007018818A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
AU2012281281B2 (en) * 2011-07-13 2017-06-01 Tiumbio Co., Ltd 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
ES2791627T3 (es) 2012-11-12 2020-11-05 Inst Catalana Recerca Estudis Avancats Métodos y kits para el pronóstico del cáncer colorrectal
PL2970890T3 (pl) 2013-03-14 2020-11-16 The Brigham And Women's Hospital, Inc. Kompozycje i sposoby ekspansji i hodowli nabłonkowych komórek macierzystych
EP3189134A1 (en) 2014-09-03 2017-07-12 The Brigham and Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
ES2918924T3 (es) 2015-04-01 2022-07-21 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
JP6856648B2 (ja) 2015-12-15 2021-04-07 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Cxcr4受容体アンタゴニスト
US11021687B2 (en) 2016-01-08 2021-06-01 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
EP4049665B1 (en) 2016-03-15 2025-03-12 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
US10604528B2 (en) 2016-07-07 2020-03-31 Crystal Pharmaceutical (Suzhou) Co., Ltd. Galunisertib crystalline form, preparation method thereof and use thereof
JP2019534266A (ja) 2016-10-14 2019-11-28 江蘇恒瑞医薬股▲ふん▼有限公司 5員ヘテロアリール環の架橋した環誘導体、その製造方法およびその医学的使用
EP3562827A1 (en) 2016-12-30 2019-11-06 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
CN110582497B (zh) * 2017-03-17 2022-03-11 杭州领业医药科技有限公司 Galunisertib的晶型及其制备方法和药物组合物
WO2018170724A1 (zh) 2017-03-21 2018-09-27 杭州领业医药科技有限公司 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶,其制备方法和药物组合物
WO2019042383A1 (zh) * 2017-08-31 2019-03-07 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
WO2019105082A1 (zh) * 2017-11-30 2019-06-06 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
WO2019137027A1 (zh) * 2018-01-12 2019-07-18 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
CN112135613A (zh) 2018-03-20 2020-12-25 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
US20210254006A1 (en) 2018-06-06 2021-08-19 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
JP2021533788A (ja) 2018-08-17 2021-12-09 フリークエンシー セラピューティクス インコーポレイテッド Jag−1を上方制御することにより有毛細胞を生成するための組成物及び方法
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
WO2020142485A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CN115282280A (zh) * 2022-08-12 2022-11-04 中国科学技术大学 TGF-β1信号抑制剂的新用途
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
GB202309553D0 (en) 2023-06-24 2023-08-09 Ucl Business Ltd Compostions and uses thereof
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ras抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287857B6 (sk) * 2001-05-24 2012-01-04 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
AU2003298611A1 (en) 2002-11-21 2004-06-18 Eli Lilly And Company Mixed lineage kinase modulators
UA80571C2 (en) * 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles

Similar Documents

Publication Publication Date Title
JP2009502780A5 (https=)
ME02307B (me) Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol- 3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfr
JP2011168587A5 (https=)
JP2009538861A5 (https=)
FI2134702T4 (fi) 6-[2-(metyylikarbamoyyli)fenyylisulfanyyli]-3-E-[2-(pyridiini-2-yyli)etenyyli]indatsolin kidemuotoja jotka soveltuvat nisäkkäiden poikkeavan solukasvun hoitamiseen
WO2010026436A3 (en) 1,3, 4, 6, 7, 11b-hexahydro-benzo[alpha]quinolizines for the treatment of hyperkinetic movement and related disorders
RU2007110026A (ru) ПОЛИМОРФНЫЕ И АМОРФНАЯ ФОРМЫ ФОСФАТНОЙ СОЛИ 8-ФТОР-2-{4-[(МЕТИЛАМИНО)МЕТИЛ]ФЕНИЛ}-1,3,4,5-ТЕТРАГИДРО-6Н-АЗЕПИНО[5.4.3-cd]ИНДОЛ-6-ОНА
WO2006053255A3 (en) Novel betulin derivatives, preparation thereof and use thereof
WO2007076348A3 (en) Azaindole inhibitors of aurora kinases
WO2009080227A3 (en) Pyrazole-carboxamide derivatives as p2y12 antagonists
WO2008012622A3 (en) Azabenzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
WO2007135527A3 (en) Benzimidazolyl compounds
JP2017519027A5 (https=)
WO2007048066A3 (en) Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators
WO2009080226A3 (en) Heterocyclic pyrazole-carboxamides as p2y12 antagonists
WO2008048867A3 (en) Bicyclic heteroaromatic compounds
JP2012512158A5 (https=)
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2010089510A3 (fr) Dérivés d'azaspiranyl-alkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique
WO2009149139A8 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2009051119A1 (ja) ピリミジルインドリン化合物
MX2007005189A (es) Derivados de quinuclidina y su uso como antagonistas del receptor muscarinico m3.
WO2009013348A3 (en) Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
WO2008072053A3 (en) Substituted arylpyrazoles
NO20092058L (no) Heteroaryl pyrrolidinyl ketonderivater